Citations

Mayo Clinic

Showing 10 of 108602 citations.

Impact of Mitral Regurgitation Recurrence on Mitral Valve Repair for Secondary Ischemic Mitral Regurgitation
Salsano, Antonio , Nenna, Antonio , Singh, Sanjeet Singh Avtaar , Spadaccio, Cristiano , Chello, Massimo , Fiore, Antonio , Nappi, Francesco , Avtaar Singh, Sanjeet Singh , Chello, Massimo , Fiore, Antonio , Nappi, Francesco , Molinari, Nicolas , Santini, Francesco

Journal of Cardiovascular Development and Disease | March 16, 2023 | Volume: 10 | Issue: 3 | Pages: 124

10.3390/jcdd10030124 | PMID 36975888 Get It

Objectives. The current guidelines still do not include specific recommendations on the use of subvalvular repair (SV-r) for treatment of ischemic mitral regurgitation (IMR). Therefore, the objective of our study was to evaluate the clinical impact of mitral regurgitation (MR) recurrence and ventricular remodeling on long-term outcomes after SV-r combined with restrictive annuloplasty (RA-r). Methods. We performed a subanalysis of the papillary muscle approximation trial, studying 96 patients with severe IMR and coronary artery disease undergoing restrictive annuloplasty alongside subvalvular repair (SV-r + RA-r group) or restrictive annuloplasty alone (RA-r group). We analyzed treatment failure differences, the influence of residual MR, left ventricular remodeling, and clinical outcomes. The primary endpoint was treatment failure (composite of death; reoperation; or recurrence of moderate, moderate-to-severe, or severe MR) within 5 years of follow-up after the procedure. Results. A total of 45 patients showed failure of the treatment within 5 years, of which 16 patients underwent SV-r + RA-r (35.6%) and 29 underwent RA-r (64.4%, p = 0.006). Patients with significant residual MR presented with a higher rate of all-cause mortality at 5 years compared with trivial MR (HR 9.09, 95% CI 2.08–33.33, p = 0.003). MR progression occurred earlier in the RA-r group, as 20 patients in the RA-r group vs. 6 in SV-r + RA-r group had a significant MR 2 years after surgery (p = 0.002). Conclusions. RA-r remains a surgical mitral repair technique with an increased risk of failure and mortality at 5 years compared with SV-r. The rates of recurrent MR are higher, and recurrence occurs earlier, with RA-r alone compared to SV-r. The addition of the subvalvular repair increases the durability of the repair, thus extending all of the benefits of preventing MR recurrence.
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study
Milgrom, Sarah A. , Kim, Ji‐Hyun , Pei, Qinglin , Lee, Inki , Hoppe, Bradford S. , Wu, Yue , Hodgson, David , Kessel, Sandy, McCarten, Kathleen M. , Roberts, Kenneth B. , Cole, Peter D. , Kelly, Kara M. , Hodgson, David C , Kelly, Kara M , Hoppe, Bradford S , Hodgson, David , Hodgson, David C. , Cho, Steve Y.

British Journal of Haematology | March 16, 2023 | Volume: 201 | Issue: 6 | Pages: 1192-1199

10.1111/bjh.18734 | PMID 36922022 Get It

SummaryThe Children's Oncology Group AHOD0831 study used a positron emission tomography (PET) response‐adapted approach in high‐risk Hodgkin lymphoma, whereby slow early responders (SERs) received more intensive therapy than rapid early responders (RERs). We explored if baseline PET‐based characteristics would improve risk stratification. Of 166 patients enrolled in the COG AHOD0831 study, 94 (57%) had baseline PET scans evaluable for quantitative analysis. For these patients, total body metabolic tumour volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax) and peak SUV (SUVpeak) were obtained. MTV/TLG thresholds were an SUV of 2.5 (MTV2.5/TLG2.5) and 40% of the tumour SUVmax (MTV40%/TLG40%). TLG2.5 was associated with event‐free survival (EFS) in the complete cohort (p = 0.04) and in RERs (p = 0.01), but not in SERs (p = 0.8). The Youden index cut‐off for TLG2.5 was 1841. Four‐year EFS was 92% for RER/TLG2.5 up to 1841, 60% for RER/TLG2.5 greater than 1841, 74% for SER/TLG2.5 up to 1841 and 79% for SER/TLG2.5 greater than 1841. Second EFS for RER/TLG2.5 up to 1841 was 100%. Thus, RERs with a low baseline TLG2.5 experienced excellent EFS with less intensive therapy, whereas RERs with a high baseline TLG2.5 experienced poor EFS. These findings suggest that patients with a high upfront tumour burden may benefit from intensified therapy, even if they achieve a RER.
Small Bowel Carcinoma in the Setting of Inflammatory Bowel Disease
Bhatt, Himani , Mathis, Kellie L.

Clinics in Colon and Rectal Surgery | March 15, 2023 | Volume: 37 | Issue: 01 | Pages: 046-052

10.1055/s-0043-1762929 | PMID 38188070 Get It

AbstractSmall bowel carcinomas are rare in the general population, but the incidence is increasing. Patients with inflammatory bowel diseases (IBDs) are at significantly higher risk of small bowel adenocarcinomas than their non-IBD counterparts, with Crohn's patients having at least a 12-fold increased risk and ulcerative colitis patients with a more controversial and modest 2-fold increased risk compared with the general population. IBD patients with small bowel carcinomas present with nonspecific symptoms that overlap with typical IBD symptoms, and this results in difficulty making a preoperative diagnosis. Cross-sectional imaging is rarely diagnostic, and most cancers are found incidentally at the time of surgery performed for an IBD indication. As such, most small bowel carcinomas are found at advanced stages and carry a poor prognosis. Oncologic surgical resection is the treatment of choice for patients with locoregional disease with little evidence available to guide adjuvant therapy. Patients with metastatic disease are treated with systemic chemotherapy, and surgery is reserved for palliation in this population. Prognosis is poor with few long-term survivors reported.
Introduction of the Lip Classification of Tubercles: A Novel Approach to Minimally Invasive Aesthetic Lip Treatments
Alfertshofer, Michael , Allen, Rory , Castellari, Fabrizio, Othoro, Don, Bran, Greg, Cotofana, Sebastian , Alfertshofer, Michael , Cotofana, Sebastian , Harris, Steven

Aesthetic Surgery Journal Open Forum | March 15, 2023 | Volume: 5 | Issue: No issue available | Pages: No page available

10.1093/asjof/ojad007 | PMID 36937993 Get It

Abstract Background Lip enhancement procedures involving dermal fillers are one of the most sought after nonsurgical aesthetic treatments. However, current trends are associated with unnatural results and involve increased risks of complications and compromise to normal function. It appears that lips may be classified according to the presentation of their tubercles and this may be used to guide minimally invasive techniques which aim to preserve individual lip shapes and normal function. Objectives To test the reliability of a classification system based on lip tubercle morphology, named the Lip Classification of Tubercles (LCT). Methods To test the reliability of the LCT, a total of 214 high-definition photographs of patients’ lips with no previous histories of lip treatments were classified independently by 4 experienced aesthetic practitioners on 2 separate occasions 3 months apart; the second followed a more detailed explanation of the classification. Results When inter-rater reliability was calculated for the first attempt, the results were 36% and 43% for upper and lower lips, respectively. The second attempt following an education process resulted in 79% for both lips. When 1 practitioner was considered the standard, the average score for the remaining 3 showed some individual variation but improved significantly from 58% to 85%. Conclusions The LCT is a reliable way to classify lip types based on the morphology of tubercles. Level of Evidence: 3
Sleep Disturbances in Cervical Spondylotic Myelopathy
Bisson, Erica F. , Mummaneni, Praveen V. , Michalopoulos, Giorgos D. , Chan, Andrew K. , Agarwal, Nitin , Wang, Michael Y. , Knightly, John J. , Sherrod, Brandon A. , Gottfried, Oren N., Than, Khoi D. , Shaffrey, Christopher I. , Virk, Michael S. , Hussain, Ibrahim , Shabani, Saman , Glassman, Steven D. , Tumialan, Louis M., Turner, Jay D. , Uribe, Juan S. , Meyer, Scott A., Lu, Daniel C. , Buchholz, Avery L., Upadhyaya, Cheerag D., Shaffrey, Mark E., Park, Paul , Foley, Kevin T. , Coric, Domagoj , Slotkin, Jonathan R., Potts, Eric A. , Stroink, Ann R., Chou, Dean , Fu, Kai-Ming, Haid, Regis W., Asher, Anthony L. , Bydon, Mohamad , Uribe, Juan S. , El Sammak, Sally, Michalopoulos, Giorgos , Sammak, Sally El , Goldberg, Jacob L.

Clinical Spine Surgery | March 15, 2023 | Volume: 36 | Issue: 3 | Pages: 112-119

10.1097/bsd.0000000000001454 | PMID 36920372 Get It

Study Design: Prospective observational study, level of evidence 1 for prognostic investigations. Objectives: To evaluate the prevalence of sleep impairment and predictors of improved sleep quality 24 months postoperatively in cervical spondylotic myelopathy (CSM) using the quality outcomes database. Summary of Background Data: Sleep disturbances are a common yet understudied symptom in CSM. Materials and Methods: The quality outcomes database was queried for patients with CSM, and sleep quality was assessed through the neck disability index sleep component at baseline and 24 months postoperatively. Multivariable logistic regressions were performed to identify risk factors of failure to improve sleep impairment and symptoms causing lingering sleep dysfunction 24 months after surgery. Results: Among 1135 patients with CSM, 904 (79.5%) had some degree of sleep dysfunction at baseline. At 24 months postoperatively, 72.8% of the patients with baseline sleep symptoms experienced improvement, with 42.5% reporting complete resolution. Patients who did not improve were more like to be smokers [adjusted odds ratio (aOR): 1.85], have osteoarthritis (aOR: 1.72), report baseline radicular paresthesia (aOR: 1.51), and have neck pain of ≥4/10 on a numeric rating scale. Patients with improved sleep noted higher satisfaction with surgery (88.8% vs 72.9%, aOR: 1.66) independent of improvement in other functional areas. In a multivariable analysis including pain scores and several myelopathy-related symptoms, lingering sleep dysfunction at 24 months was associated with neck pain (aOR: 1.47) and upper (aOR: 1.45) and lower (aOR: 1.52) extremity paresthesias. Conclusion: The majority of patients presenting with CSM have associated sleep disturbances. Most patients experience sustained improvement after surgery, with almost half reporting complete resolution. Smoking, osteoarthritis, radicular paresthesia, and neck pain ≥4/10 numeric rating scale score are baseline risk factors of failure to improve sleep dysfunction. Improvement in sleep symptoms is a major driver of patient-reported satisfaction. Incomplete resolution of sleep impairment is likely due to neck pain and extremity paresthesia.
Is Severe Neck Pain a Contraindication to Performing Laminoplasty in Patients With Cervical Spondylotic Myelopathy?
Pinter, Zachariah W. , Mikula, Anthony L. , Reed, Ryder, Lakomkin, Nikita , Townsley, Sarah E., Wright, Breydan, Kazarian, Erick R., Michalopoulos, Giorgos D. , Currier, Bradford L. , Freedman, Brett A. , Bydon, Mohamad , Elder, Benjamin D. , Fogelson, Jeremy L. , Sebastian, Arjun S. , Fogelson, Jeremy, Michalopoulos, Giorgos , Nassr, Ahmad

Clinical Spine Surgery | March 15, 2023 | Volume: 36 | Issue: 3 | Pages: 127-133

10.1097/bsd.0000000000001444 | PMID 36920406 Get It

Study Design: Retrospective review. Objective: The purpose of this study was to investigate the surgical outcomes in a cohort of patients with severe preoperative axial neck pain undergoing laminoplasty for cervical spondylotic myelopathy (CSM). Summary of Background Data: No study has investigated whether patients with severe axial symptoms may achieve satisfactory neck pain and disability outcomes after laminoplasty. Methods: We performed a retrospective review of 91 patients undergoing C4-6 laminoplasty for CSM at a single academic institution between 2010 and 2021. Patient-reported outcome measures (PROMs), including Neck Disability Index (NDI), visual analog scale (VAS) Neck, and VAS Arm, were recorded preoperatively and at 6 months and 1 year postoperatively. Patients were stratified as having mild pain if VAS neck was 0–3, moderate pain if 4–6, and severe pain if 7–10. PROMs were then compared between subgroups at all the perioperative time points. Results: Both the moderate and severe neck pain subgroups demonstrated a substantial improvement in VAS neck from preoperative to 6 months postoperatively (−3.1±2.2 vs. −5.6±2.8, respectively; P<0.001), and these improvements were maintained at 1 year postoperatively. There was no difference in VAS neck between subgroups at either the 6-month or 1-year postoperative time points. Despite the substantially higher mean NDI in the moderate and severe neck pain subgroups preoperatively, there was no difference in NDI at 6 months or 1 year postoperatively (P=0.99). There were no differences between subgroups in the degree of cord compression, severity of multifidus sarcopenia, sagittal alignment, or complications. Conclusions: Patients with moderate and severe preoperative neck pain undergoing laminoplasty achieved equivalent PROMs at 6 months and 1 year as patients with mild preoperative neck pain. The results of this study highlight the multifactorial nature of neck pain in these patients and indicate that severe axial symptoms are not an absolute contraindication to performing laminoplasty in well-aligned patients with CSM.
Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression
Tritz, Zachariah P. , Ayasoufi, Katayoun , Wolf, Delaney M. , Owens, Carley A. , Malo, Courtney S. , Himes, Benjamin , Fain, Cori E. , Goddery, Emma N. , Yokanovich, Lila T. , Jin, Fang , Hansen, Michael J. , Wang, Chensu , Marcano, Rosa M. Diaz , Vile, Richard G. , Johnson, Aaron J. , Himes, Benjamin T , Parney, Ian F , Wang, Chensu , Moynihan, Kelly D , Irvine, Darrell J , Wittrup, K Dane , Diaz Marcano, Rosa M , Vile, Richard G , Johnson, Aaron J. , Ayasoufi, Katayoun , Parney, Ian F.

Cancer Immunology Research | March 15, 2023 | Volume: 11 | Issue: 6 | Pages: 763-776

10.1158/2326-6066.cir-22-0570 | PMID 36921098 Get It

Abstract Glioblastoma (GBM) is the most common malignant brain tumor in adults, responsible for approximately 225,000 deaths per year. Despite preclinical successes, most interventions have failed to extend patient survival by more than a few months. Treatment with anti—programmed cell death protein 1 (anti–PD-1) immune checkpoint blockade (ICB) monotherapy has been beneficial for malignant tumors such as melanoma and lung cancers but has yet to be effectively employed in GBM. This study aimed to determine whether supplementing anti–PD-1 ICB with engineered extended half-life IL2, a potent lymphoproliferative cytokine, could improve outcomes. This combination therapy, subsequently referred to as enhanced checkpoint blockade (ECB), delivered intraperitoneally, reliably cures approximately 50% of C57BL/6 mice bearing orthotopic GL261 gliomas and extends median survival of the treated cohort. In the CT2A model, characterized as being resistant to CBI, ECB caused a decrease in CT2A tumor volume in half of measured animals similar to what was observed in GL261-bearing mice, promoting a trending survival increase. ECB generates robust immunologic responses, features of which include secondary lymphoid organ enlargement and increased activation status of both CD4 and CD8 T cells. This immunity is durable, with long-term ECB survivors able to resist GL261 rechallenge. Through employment of depletion strategies, ECB's efficacy was shown to be independent of host MHC class I–restricted antigen presentation but reliant on CD4 T cells. These results demonstrate ECB is efficacious against the GL261 glioma model through an MHC class I–independent mechanism and supporting further investigation into IL2-supplemented ICB therapies for tumors of the central nervous system.
An Unusual Cause of GI Blood Loss
Travers, Paul , Pang, Maoyin , Travers, Paul M

ACG Case Reports Journal | March 15, 2023 | Volume: 10 | Issue: 3 | Pages: e00992

10.14309/crj.0000000000000992 | PMID 36936130 Get It

ABSTRACT Chronic gastrointestinal bleeding is the leading cause of iron deficiency anemia in developed countries, and most occult bleeds are attributed to upper gastrointestinal tract lesions, which are broadly categorized into mass lesions, vascular, infectious, and inflammatory abnormalities. Gastric polyps account for an exceedingly small portion of these lesions but are of clinical importance because of the risk for progression to malignancy. We describe a patient found to have a gastric foveolar-type adenoma as a rare cause of iron deficiency anemia, with an incidentally found gastric neuroendocrine tumor.
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders
Nugent, Diane J. , Acharya, Suchitra S. , Baumann, Kimberly J., Bedrosian, Camille L. , Bialas, Rebecca, Brown, Kai , Corzo, Deya, Haidar, Amar, Hayward, Catherine P.M. , Miller, Margaret E., Nammacher, Kate, Peltier, Skye , Pruthi, Rajiv K. , Sørensen, Benny, Tarantino, Michael D. , Wolberg, Alisa S. , Menegatti, Marzia , Palla, Roberta , Peltier, Skye , Pruthi, Rajiv K , Recht, Michael , Wolberg, Alisa S , Shapiro, Amy D , Baumann, Kimberly, Corzo, Deyanira , Marks, Peter

Expert Review of Hematology | March 15, 2023 | Volume: 16 | Issue: sup1 | Pages: 55-70

10.1080/17474086.2023.2175661 | PMID 36920862 Get It

A Community Paramedic Clinic at a Day Center for Adults Experiencing Homelessness
Ridgeway, Jennifer L. , Finnie, Dawn M., Wiepert, Liana M , Glasgow, Amy E. , Torres, Andrew J., Juntunen, Michael B. , Liedl, Chad P., Ridgeway, Jennifer L , Gerdes, Erin O. Wissler , Zhu, Xuan , Torres, Andrew J., Smith, Olivia A., McCoy, Rozalina G.

NEJM Catalyst | March 15, 2023 | Volume: 4 | Issue: 4 | Pages: No page available

10.1056/cat.22.0300 Get It